Evolution of the Average Target: Virbac

Evolution of the Target Price: Virbac

Changes in Analyst Recommendations: Virbac

3114a158c5fb00baa091.89D_Oi1q3wXHD7NOSarEED93eribq1oSqvjfwvxcEWw.hainQ34kmmiiN-pjBtKFWEwYMdr6xBglxqCPjLMDVT2FmMgCSjq6cKk38g~3022e980beeb6123ece3a692451a1fec
08-20 Cancer vaccines finally garner the spotlight Alphavalue
07-21 Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 Alphavalue
07-14 Where would AI lead Pharma in the long run? Alphavalue
05-11 Virbac continues decline despite positive recommendation Zonebourse
04-17 Virbac: 2026 starts on strong footing Alphavalue
03-19 Stifel sees Virbac as undervalued, sets 440 euro price target Zonebourse
03-18 Virbac in the green following results and outlook Zonebourse
01-20 Virbac beats 2025 targets, lifts 2026 outlook Alphavalue
01-20 Stifel Raises Price Target on Virbac Zonebourse
01-20 Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets Zonebourse
17/10/25 Virbac: Q3 crushed doubts about execution ability Alphavalue
17/09/25 The day the Fed resumed its rate cuts Zonebourse
15/09/25 Virbac: Oddo BHF remains positive despite H1 results Zonebourse
17/07/25 Virbac: A healthy Q2 impresses the markets Alphavalue
03/07/25 Oddo BHF Upgrades Virbac to Outperform, Boosts PT MT
03/07/25 Virbac: Oddo BHF upgrades stock Zonebourse
17/04/25 Virbac: brokers' advice following quarterly results Zonebourse
16/04/25 Virbac: Stifel remains bullish after quarterly results Zonebourse
16/04/25 Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway Alphavalue
16/04/25 Virbac: Stifel still buying after Q1 results Zonebourse
17/03/25 Virbac: Oddo BHF remains 'neutral', confirms its target Zonebourse
17/03/25 Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway Alphavalue
17/03/25 Virbac: Stifel raises its recommendation Zonebourse
17/01/25 Virbac: 2024 top-line goals met; uninspiring 2025 outlook could be raised later Alphavalue
17/01/25 Oddo BHF Downgrades Virbac to Neutral, Cuts PT MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+24.51%
+30.49%
+100.81%
+27.71%
+14.26%
+4.36%
- +16.59%
+17.98%
- +31.77%
Average +29.83%
Weighted average by Cap. +29.82%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
322.50EUR
Average target price
411.88EUR
Spread / Average Target
+27.71%
High Price Target
440.00EUR
Spread / Highest target
+36.43%
Low Price Target
360.00EUR
Spread / Lowest Target
+11.63%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA